| Date | Name | Shares | Transaction | Value |
|
Jul 29, 2025
| Sam A. Eldessouky EVP and CFO |
278,299
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share |
3,985,241.68
|
|
Jul 29, 2025
| Luc Bonnefoy President, Surgical |
71,216
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share |
1,019,813.12
|
|
Jul 29, 2025
| Yehia Hashad EVP of R&D and CMO |
116,739
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share |
1,671,702.48
|
|
Jul 29, 2025
| Frederick J. Munsch SVP, Controller and CAO |
70,204
| Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $14.32 per share |
1,005,321.28
|
|
Mar 3, 2025
| Brenton L. Saunders CEO and Chairman of the Board; Director |
697,156
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Brenton L. Saunders CEO and Chairman of the Board; Director |
600,858
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Sam A. Eldessouky EVP and CFO |
141,630
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Ambrose Robert Douglas Bailey EVP & Chief Legal Officer |
180,357
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Ambrose Robert Douglas Bailey EVP & Chief Legal Officer |
96,566
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Luc Bonnefoy President,Surgical |
55,793
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Andrew J. Stewart See remarks |
66,884
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Andrew J. Stewart See remarks |
55,793
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|
|
Mar 3, 2025
| Yehia Hashad EVP of R&D and CMO |
60,085
| Grant, award or other acq pursuant to Rule 16b-3(d) |
0.00
|